Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 5/20 | 0.56 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 4/20 | 0.48 |
| ▸ | MMP9 | P14780 | 4/20 | 0.48 |
| ▸ | MMP8 | P22894 | 4/20 | 0.48 |
| ▸ | MMP13 | P45452 | 4/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | SCD | O00767 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.45 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL810467 | 0.84 | MAPT (0.52) | CHEK2PTGESALOX5LTC4SMMP2 | |
| SCHEMBL810353 | 0.77 | KDR (0.42) | CHEK2PTGESALOX5LTC4SMMP2 | |
| SCHEMBL810595 | 0.75 | MET (0.41) | CHEK2PTGESALOX5LTC4SMMP2 | |
| SCHEMBL17973888 | 0.74 | CHEK2 (0.67) | CHEK2PTGESALOX5LTC4SSCD | |
| SCHEMBL810587 | 0.73 | MMP2 (0.48) | CHEK2MMP2MMP9MMP8MMP13 | |
| SCHEMBL12470982 | 0.73 | PRMT5 (0.70) | CHEK2PTGESALOX5LTC4SPRMT5 | |
| SCHEMBL7652411 | 0.72 | MMP13 (0.73) | MMP2MMP9MMP8MMP13TRPV1 | |
| SCHEMBL31289493 | 0.71 | CHEK2 (0.61) | CHEK2PTGESALOX5LTC4SPRMT5 | |
| SCHEMBL484162 | 0.71 | CHEK2 (0.57) | CHEK2PTGESALOX5LTC4SSCD | |
| SCHEMBL15288339 | 0.69 | MMP13 (0.71) | CHEK2MMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971611-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-2345652-A1 | Antiviral compounds | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7915411-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1971611-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007081517-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | CHEK2 4511/4885PTGES 1433/4885ALOX5 2999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.